WuXi Biologics enters first commercial manufacturing agreement
WuXi Biologics agrees five-year deal with Amicus for the commercial production of a biologic for the treatment of Pompe disease.
Archives for February 13, 2019
Biotech licenses protein production tech to Eli Lilly
ProteoNic licenses its 2G UNic technology to Eli Lilly for the development of the latter’s proprietary products.
Clinigen pays Novartis $210m for US rights to Proleukin
Clinigen has agreed to acquire the global rights for Proleukin, after Novartis accepted a $210m fee in exchange for the asset.